CD38 and Miyoshi myopathy: Because of the clinically meaningful anti-myeloma activity and manageable safety profile of Belamaf from the first report, it was approved by the FDA in 2020 as a monotherapy treatment for R/R MM patients who have received 4 prior therapies including anti-CD38 mAb, PI, and IMiDs.